Non-vitamin K antagonist oral anticoagulants (NOAC) are increasingly used for treatment and prophylaxis of thromboembolic disease given their safety profile, effectiveness, and fewer drug interactions than vitamin K antagonists (VKA). Although the incidence reported in studies of severe bleeding, especially intracranial, is lower than with VKAs, the increasing use of NOACs results in a higher frequency of bleeding episodes. The pharmacological and pharmacodynamic profile of NOACs, as well as the coagulation tests that are useful to evaluate their activity is relevant. In recent years, specific reverse drugs have been developed for the anticoagulant activity of NOACs, as well as 14 recommended strategies for the general management of bleeding associated with them.
Morales, N., & Cordero, M. J. (2021). Reversal of anticoagulation with non-vitamin k antagonist oral anticoagulants (NOACs). Boletín De Anestesia, (2), pp. 13–20. Retrieved from https://boletinanestesia.uchile.cl/index.php/BA/article/view/64530
